A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2001
11/08/2001	WO2001084158A1 Use of the g protein coupled receptor gpr3 to identify appetite control agents
11/08/2001	WO2001084149A2 Diagnostics and therapeutics for macular degeneration-related disorders
11/08/2001	WO2001083782A2 Novel proteases
11/08/2001	WO2001083775A2 Proteases
11/08/2001	WO2001083772A1 Splice variant of camp phosphodiesterase type 7 (pde7a3)
11/08/2001	WO2001083746A2 Regulatory nucleic acid sequences of the abc1 gene
11/08/2001	WO2001083744A2 Natrium-calcium exchanger protein
11/08/2001	WO2001083698A2 Compositions and methods for inducing activation of dendritic cells
11/08/2001	WO2001083560A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	WO2001083558A1 Agonists/antagonists of the gpr56 receptor as appetite control agents
11/08/2001	WO2001083555A2 Pain signaling molecules
11/08/2001	WO2001083550A2 Gpr22 modulators as appetite-control agents
11/08/2001	WO2001083524A2 Rna metabolism proteins
11/08/2001	WO2001083496A1 Bis-(n,n'-bis-(2-haloethyl)amino) phosphoramidates as antitumor agents
11/08/2001	WO2001083477A1 Stolonoxides
11/08/2001	WO2001083462A1 Novel, slow-acting betamimetics, a method for their production and their use as medicaments
11/08/2001	WO2001083457A2 Benzimidazole-2-carbamates and their use in cancer treatment
11/08/2001	WO2001083439A2 Novel $g(y) crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
11/08/2001	WO2001083031A2 Topical composition for the treatment of psoriasis and related skin disorders
11/08/2001	WO2001082970A1 Mixtures of triblock polyesterpolyethylene glycol copolymers
11/08/2001	WO2001082969A2 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
11/08/2001	WO2001082965A1 Combination therapy of respiratory diseases using antibodies
11/08/2001	WO2001082956A1 Pharmaceutical composition
11/08/2001	WO2001082949A2 Method of reducing side effects of chemotherapy in cancer patients
11/08/2001	WO2001082937A1 Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use
11/08/2001	WO2001082935A1 Remedies for cancer
11/08/2001	WO2001082932A2 Methods and compositions for enhancing cellular function through protection of tissue components
11/08/2001	WO2001082928A1 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
11/08/2001	WO2001082920A2 Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist
11/08/2001	WO2001082919A2 Methods of and compounds for inhibiting calpains
11/08/2001	WO2001082916A2 Combination therapeutic compositions and methods of use
11/08/2001	WO2001082914A2 Topical anesthetic/opioid formulations and uses thereof
11/08/2001	WO2001082911A2 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
11/08/2001	WO2001082897A2 Liposome drug delivery
11/08/2001	WO2001082873A2 A medicinal aerosol formulation
11/08/2001	WO2001082872A2 A medicinal aerosol formulation
11/08/2001	WO2001082868A2 A medicinal aerosol formulation
11/08/2001	WO2001082863A2 Polyacid/polyalkylene oxide foams and gels and methods for their delivery
11/08/2001	WO2001082861A2 Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters
11/08/2001	WO2001082780A2 Method for treating cancer, visualizing cell structures, and isolating organelles using organelle crystallizing agents
11/08/2001	WO2001060349A3 Pharmacological agent comprising picolinic acid, fusaric acid and derivatives thereof.
11/08/2001	WO2001044242A9 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
11/08/2001	WO2001041801A3 Mutant simplex virus for treating unwanted hyperproliferative cell growth
11/08/2001	WO2001041760A3 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
11/08/2001	WO2001040460A8 Screening method for compounds capable of modularing egr-1-regulated expression
11/08/2001	WO2001039777A8 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
11/08/2001	WO2001038564A3 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
11/08/2001	WO2001030383A3 Medicament in order to induce tolerance
11/08/2001	WO2001017516A3 Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
11/08/2001	WO2001002551A3 Virus like particles, preparation and use in screening and functional genomics
11/08/2001	WO2000076556A9 High dose radionuclide complexes for bone marrow suppression
11/08/2001	WO2000074666A3 Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia
11/08/2001	WO2000069897A3 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes
11/08/2001	US20010039479 Three-dimensional model of a Fc region of an IgE antibody and uses thereof
11/08/2001	US20010039438 Method for treating neovascularization
11/08/2001	US20010039411 Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same
11/08/2001	US20010039295 Transfusional iron overload
11/08/2001	US20010039293 4((4-chloro-3-hydroxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydro -naphathalene-2-carbonyl)-amino)-2,6-difluoro-benzoic acid or its esters or salts used as agonists of alpha-retinoid receptors (=raralpha)
11/08/2001	US20010039282 Desloratadine as non-sedating antihistamine, decongestant
11/08/2001	US20010039280 Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists
11/08/2001	US20010039262 Methods and compositions for the treatment of cardiac indications
11/08/2001	US20010039258 Exposing biologically active agent to complexing perturbant to reversibly transform biologically active agent to intermediate state and to form a subcutaneously deliverable supramolecular complex, subcutaneously administering complex
11/08/2001	US20010039257 Augmenting actions of cAMP in an effector system while reducing cAMP action in a nociceptive system comprising application of one or more forms of nitrogen oxide or carbon monoxide to a site wherein cAMP exists
11/08/2001	US20010039041 Immunosuppressive sesbanimide compositions and methods of treatment using same
11/08/2001	US20010039038 Novel glucosaminidase
11/08/2001	US20010039027 Cyclitol containing carbohydrates from human tissue which regulate lipogenic activity
11/08/2001	US20010039026 Assay method
11/08/2001	US20010039017 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
11/08/2001	US20010039016 Measurement, calibration gene expression
11/08/2001	US20010038863 Modifying the effect of a first drug by adding a second drug; soporific agent and a stimulant for example
11/08/2001	US20010038853 Suspending a pore-forming agent in an aqueous dispersion of a film-forming, water insoluble polymer to form a coating suspension having solid particles of pore former suspended therein, and coating a drug-containing solid core, drying
11/08/2001	US20010038849 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
11/08/2001	US20010038846 Applying glycolic acid to the keloid scar long enough to promote atrophy of the damaged skin; nontoxic, inexpensive
11/08/2001	US20010038842 Treating a disease characterized by expression of vascular endothelial growth factor-D (VEGF-D) by a tumor by screening for a VEGF-D expressing tumor, administering a VEGF-D antagonist to prevent binding of VEGF-D to its receptor
11/08/2001	US20010038838 Empiric treatment of infections potentially caused by drug resistance streptococcus pneumoniae in a human patient comprising the oral administration of a formulation comprising amoxycillin and potassium clavulanate
11/08/2001	US20010038827 Inhalation comprising an effective amount of a vesicant and a pharmeceutically acceptable carrier, wherein the vesicant does not exhibit substantial toxicity while treating a patient for neoplasm
11/08/2001	US20010038826 Inhalation comprising an effective amount of a vesicant and a pharmeceutically acceptable carrier, wherein the vesicant does not exhibit substantial toxicity while treating a patient for neoplasm
11/08/2001	US20010038825 Method and compositions for enhancing pulmonary function and treating pulmonary disorders
11/08/2001	DE10018098A1 Treatment of cancer by apoptosis induction comprises administration of amino acid and saturated fatty acid derivatives
11/08/2001	CA2409689A1 Combination therapy of respiratory diseases using antibodies
11/08/2001	CA2408105A1 Novel proteases
11/08/2001	CA2407965A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	CA2407887A1 Natrium-calcium exchanger protein
11/08/2001	CA2407824A1 Pharmaceutical composition
11/08/2001	CA2407807A1 Stolonoxides
11/08/2001	CA2407746A1 Proteases
11/08/2001	CA2407737A1 Regulatory nucleic acid for the abc1 gene, molecules modifying its activity and therapeutic uses
11/08/2001	CA2407700A1 Compositions and methods for inducing activation of dendritic cells
11/08/2001	CA2407604A1 Splice variant of camp phosphodiesterase type 7 (pde7a3)
11/08/2001	CA2407435A1 Rna metabolism proteins
11/08/2001	CA2407338A1 Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
11/08/2001	CA2407235A1 Hemostatic compositions of polyacids and polyalkylene oxides and methods for their use
11/08/2001	CA2407219A1 Pain signaling molecules
11/08/2001	CA2407129A1 Medicinal formulation comprising pioglitazone
11/08/2001	CA2405745A1 New betamimetics having a long-lasting activity, processes for preparingthem and their use as medicaments
11/07/2001	EP1152243A1 DIagnosis of Sjögren's syndrome, systemic lupus erythematosis, and scleroderma via detection of anti-retroviral antibodies
11/07/2001	EP1152055A1 ADAMTS polypeptides, nucleic acids encoding them, and uses therof
11/07/2001	EP1151752A2 Method for inhibiting bone resorption
11/07/2001	EP1151113A2 Human peptidases
11/07/2001	EP1151092A1 Inhibiting formation of atherosclerotic lesions

1 ... 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 ... 1151